Back grey_arrow_rt.gif
ADAP Crisis Task Force Announces Enhanced Support From Janssen Therapeutics (Tibotec) for ADAPs in the United States
  December 8, 2011, Washington, DC - As part of ongoing efforts by the ADAP Crisis Task Force (ACTF) and the pharmaceutical industry to address the growing need for access to antiretroviral medicines through AIDS Drug Assistance Programs (ADAP), the ACTF announced today that it has reached an enhanced agreement with Janssen Therapeutics, Division of Janssen Products, LP. The agreement provides additional voluntary discounts and rebates for all Janssen Therapeutics products purchased by ADAPs. These discounts and rebates, available to all state ADAPs, are in addition to those mandated by current law and health reform and to those included in previous agreements between the ACTF and Janssen Therapeutics. This enhanced agreement also continues a price freeze on Janssen's HIV medications purchased by ADAPs through 2013.

The ACTF, convened by the National Alliance of State and Territorial AIDS Directors (NASTAD), previously had secured significant multi-year, voluntary discounts and rebates from all eight manufacturers of HIV antiretroviral (ARV) medications, with many of them providing price freezes for ADAPs through 2013. Recently, the ACTF also reached enhanced agreements with Gilead Sciences and Boehringer Ingelheim for additional voluntary discounts and rebates on their products.

"The fiscal crisis many ADAPs are experiencing requires a shared responsibility and new commitments on the part of federal and state governments and pharmaceutical companies," stated Dwayne Haught, a member of the ACTF and Manager of the Texas ADAP. "We praise Janssen for their keen understanding of the current ADAP crisis and their commitment to helping bridge the gap ADAPs are experiencing in providing life-saving medications to more than 200,000 HIV-positive Americans," Haught added.

ADAPs yield savings from these agreements with pharmaceutical companies, however, the ongoing state budget crises, coupled with the increased numbers of clients seeking ADAP services, continues to require increased state and federal funding in addition to these cost savings. President Obama recently announced the availability of an additional $35 million for ADAP.

The increased funding for ADAP will support grants to states to help provide additional access to life-saving medications for people living with HIV/AIDS.

"We commend the President for taking this bold action to address the ADAP crisis, despite the tough fiscal environment," stated Julie Scofield, Executive Director of NASTAD. "With this voluntary agreement with Janssen now in place, other companies at the table, and additional federal funding, we again call upon Congress to provide a continuation of the $35 million new ADAP funds as well as an additional increase in FY2012 to ease access restrictions in ADAPs nationwide," noted Scofield. "We also urge state legislatures to maintain and increase their support of ADAPs during this critical period," she concluded.

While the need for ADAP funding is much greater and a higher funding level is necessary, NASTAD and community partners are advocating for an increase of $55 million in FY2012 ADAP funds from the federal government, commensurate with President Obama's FY2012 budget request.

As of December 2, there were 4,274 individuals in 12 states on waiting lists to receive ADAP medications. Eighteen ADAPs, including nine with current waiting lists, have instituted additional cost-containment measures since April 1, 2009 (reported as of November 9, 2011) and, nine ADAPs, including two with current waiting lists, are considering implementing new or additional cost-containment measures by the end of ADAP's current fiscal year (March 31, 2012). To view a list of current ADAP access restrictions, please visit

About the ACTF and NASTAD

The ACTF was formed in December 2002 by NASTAD and a group of state AIDS/ADAP directors concerned about the fiscal crisis facing ADAPs nationwide. The ACTF works in partnership with manufacturers of ARVand other HIV-related medications to reduce drug costs and improve access to medications for clients in the nation's ADAPs. It is estimated that ACTF agreements with companies have saved ADAPs approximately $1.2 billion since 2003. NASTAD provides logistical support to the ACTF.

Founded in 1992, NASTAD is a nonprofit national association of state and territorial health department HIV/AIDS program directors who have programmatic responsibility for administering HIV/AIDS and viral hepatitis health care, prevention, education, and supportive services programs funded by state and federal governments. For more information, visit


  icon paper stack View Older Articles   Back to Top